Other
Dexmedetomidine
5
Pipeline Programs↗
77
Active Trials↗
6
Companies Involved↗
Dexmedetomidine is an early-stage landscape with 5 programs across 6 companies. The most active players are Dr. Naveed Siddiqui, Cloudbreak Therapeutics, LLC, McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.. 2 therapies are approved.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical1
Phase 1
No programs
Phase 3
No programs
Analysis
Trial Status
423
clinical trials
Completed237 · 56%
Unknown status84 · 20%
Recruiting42 · 10%
Not yet recruiting28 · 7%
Withdrawn16 · 4%
Terminated8 · 2%
Other8 · 2%
Clinical Trials
Trial Activity
423 trials
Dexmedetomidine vs Midazolam in Coronary Artery By-pass Surgery
Recruiting·—·N/A·NCT07411794·60 enrolled
Effect of Sublingual Formulation of Dexmedetomidine Hydrochloride (HCl) (BXCL501) - Outpatient Study
Recruiting·PPharmacotherapies for Alcohol and Substance Use Disorders Alliance·Phase 1·NCT06335407·10 enrolled
Dexmedetomidine Versus Dexamethasone as Adjuvants to Bupivacaine for Intermediate Cervical Plexus Block
Recruiting·—·Phase 4·NCT05793060·60 enrolled
Page 1 of 29
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)